BROADENED REIMBURSEMENT CRITERIA FOR THE PARP INHIBITOR OLAPARIB

March 2022 Pharma News Tom Feys

Since 2015, Olaparib has been reimbursed as maintenance treatment of platinum-sensitive relapsed high-grade ovarian cancer patients harboring a BRCA1/2-mutation (germline and/or somatic). In 2020, this reimbursement was expanded to also include maintenance treatment of 1st line platinum-sensitive high-grade epithelial advanced ovarian cancer with a BRCA1/2-mutation (germline and/or somatic).1 From April 1st 2022 onwards, the reimbursement criteria for olaparib will be broadened further to include three additional indications:2

Olaparib will be reimbursed as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and a BRCA1/2-mutation (germline and/or somatic) who have progressed following prior therapy with a new hormonal agent and are not eligible for a treatment with docetaxel (progression or intolerance or contra-indication) and cabazitaxel (contra-indication).

Olaparib will also be eligible for reimbursement as monotherapy for the maintenance treatment of adult patients with a germline BRCA1/2-mutations and a metastatic adenocarcinoma of the pancreas who did not progress after a minimum of 16 weeks of platinum within a first-line chemotherapy regimen. Finally, olaparib will also be reimbursed as monotherapy for the treatment of adult patients with locally advanced or metastatic triple negative breast cancer with a germline BRCA1/2-mutation, and who have been previously treated with anthracycline and taxane in the (neo)adjuvant stage or metastatic stage (unless ineligible for these treatments).

X